SecBot SecBot

MNPR

Monopar Therapeutics
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001645469 Biotech & Drug Discovery
$71.84 +1.30 (+1.84%)
Oct 27 4:00 PM ET · prev $70.54
Market cap
$474.2M
Small cap
Consensus
Buy
89% Buy or better · 19 analysts
Median target
$130.00
+81% · range $119.00–145.00
Next earnings
Nov 11
in 15 days · EPS est. −$0.85
1 year
−10.1%
from $79.92 · Oct 28
30 days
−14.2%
from $83.72
52-week range
$50.12–123.84
−42% from high · low Apr 29
Avg volume 20D
140.2K
shares / day
Short interest
1.13M
≈16.8% of shares · +3.9%
Days to cover
7.1
at average volume
Insider net
−$4.1M
0 buyers · 5 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
SecBot read MIXED 9 reports · 90 days
Balance 1 bearish · 2 bullish · 1 mixed · 5 neutral oldest → newest, height = score
Avg score ·High conf. 3/9 ·Next Earnings date, Nov 11, 2026
Strongest BEARISH Monopar Therapeutics insiders executed a cluster of non-cash derivative exercises and tax-withholding share…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $4.1M.

  • InstitutionsMIXED

    Q2 2026: 11 added (1 new), 8 trimmed or exited. Largest new: Candriam S.C.A $13.3M.

  • AnalystsBULLISH

    17 of 19 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.766 → −$0.853 over 90 days. 1 up, 5 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.9% to 1.13M shares. 7.1 days to cover, ≈16.8% of shares.

  • TrendDOWNTREND

    23% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$13.3M
in new stakes
FundMoveSharesValue
ADAGE CAPITAL PARTNERS GP, L.L.C.TRIM209,195$19.4M
Candriam S.C.A.NEW143,339$13.3M
DRIEHAUS CAPITAL MANAGEMENT LLCDOUBLED84,040$7.8M
Neuberger Berman Group LLCADD55,194$5.1M
CITADEL ADVISORS LLCTRIM37,004$3.4M
UBS Group AGTRIM27,259$2.5M
AMERIPRISE FINANCIAL INCDOUBLED17,800$1.6M
GOLDMAN SACHS GROUP INCTRIM16,161$1.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 89% rate it Buy or better
Strong Buy4Buy13Hold2Sell0Strong Sell0
12-month targets · 12 analysts

Price is below the lowest target. Median implies +81%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 11, 2026Barclays
MAINTAIN
MAINTAINOverweight
Aug 13, 2026Barclays
MAINTAIN
MAINTAINOverweight
Aug 13, 2026Cantor Fitzgerald
DOWNGRADE
DOWNGRADENeutral
Aug 12, 2026BTIG
MAINTAIN
MAINTAINBuy
Jul 22, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jun 30, 2026BTIG
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$4.1M
sold · 5 insiders
DateInsiderTypeValue
Oct 20, 2026
Robinson Chandler
Chief Executive Officer
TAX W/H$55.3K
Oct 1, 2026
STARR CHRISTOPHER M
Director
SELL$63.7K
Oct 1, 2026
STARR CHRISTOPHER M
Director
SELL$234.1K
Oct 1, 2026
STARR CHRISTOPHER M
Director
SELL$361.6K
Oct 1, 2026
STARR CHRISTOPHER M
Director
EXERCISE$42.00
Sep 30, 2026
Vu Quan Anh
Chief Financial Officer
EXERCISE614 sh
Sep 30, 2026
Vu Quan Anh
Chief Financial Officer
TAX W/H$14.3K
Sep 30, 2026
Robinson Chandler
Chief Executive Officer
EXERCISE9,801 sh

Earnings setup

Estimates
Nov 11
reports in 15 days
−$0.85
EPS estimate, this quarter
−11%
estimate change, 90 days
1↑ 5↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.85-$1.37–-$0.37-2.0%$0.00
Next Q-$1.13-$2.77–-$0.43-3.9%$0.00
Current FY-$3.04-$5.25–-$1.88-1.2%$0.00
Next FY-$1.92-$5.30–$7.11+3.2%$28.3M

Short side

FINRA· Oct 15, 2026
1,128,617
shares short
+3.9%
vs prior settlement
7.1
days to cover
≈16.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 27, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 20, 2026 Insider
Robinson Chandler surrendered for taxes 597 shares
Chief Executive Officer @ $92.59 ($55.3K)
Oct 5, 2026 SEC
Monopar Therapeutics insiders executed a cluster of non-cash derivative exercises and tax-withholding share surrenders…
CLUSTER — Impact 4/10
Oct 1, 2026 Insider
STARR CHRISTOPHER M sold 799 shares
Director @ $79.67 ($63.7K)
Oct 1, 2026 Insider
STARR CHRISTOPHER M sold 2,970 shares
Director @ $78.82 ($234.1K)
Sep 30, 2026 Short interest report
Short Interest: MNPR up 29% to 1.1M shares
Settlement 2026-09-30 | Days to cover: 6.02 | ≈16.18% of shares outstanding (est.)
Jul 22, 2026 Press
Monopar Therapeutics initiated a rolling NDA submission to the FDA for ALXN1840 (tiomolibdate choline), a…
Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
MNPR Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Sep 30, 2026
Short interest
Short Interest: MNPR up 29% to 1.1M shares
Settlement 2026-09-30 | Days to cover: 6.02 | ≈16.18% of shares outstanding (est.)
Aug 19, 2026
Leadership
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage…
Aug 12, 2026
Earnings
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage…
Aug 10, 2026
Earnings date
MNPR Q2 2026 Earnings Scheduled — 2026-08-10
Jul 31, 2026
Short interest
Short Interest: MNPR down 22% to 1.1M shares
Settlement 2026-07-31 | Days to cover: 3.40 | ≈15.90% of shares outstanding (est.)

SecBot reports

18 filings · 4 press releases · 8 bullish · 1 bearish · 1 mixed · 8 neutral
All MNPR filing & press-release reports (22)